Tag
An unnamed pharmaceutical stock has outperformed the S&P 500 over a ten-year period, according to a new report. Sustained outperformance in drug equities typically reflects durable patent protection, pricing power, and pipeline execution compounding over time.
Mesoblast Limited (MESO) has been identified as one of the best long-term ASX stocks to buy, spotlighting the Australian cell therapy biotech's multi-year investment case. The company's mesenchymal stromal cell platform and regulatory progress underpin the bullish thesis. Key watch points include pipeline milestones
Tag
An unnamed pharmaceutical stock has outperformed the S&P 500 over a ten-year period, according to a new report. Sustained outperformance in drug equities typically reflects durable patent protection, pricing power, and pipeline execution compounding over time.
2mo ago · 1 min · Markets
Mesoblast Limited (MESO) has been identified as one of the best long-term ASX stocks to buy, spotlighting the Australian cell therapy biotech's multi-year investment case. The company's mesenchymal stromal cell platform and regulatory progress underpin the bullish thesis. Key watch points include pipeline milestones
2mo ago · 1 min · Markets
— End of feed —